Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

A member of the U.K. Parliament is calling for regulators to audit pharmaceutical companies that have made misleading ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 17,464.11 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...